Fasoracetam clinical trials
Also written AEVI-001 and MDGN-001.
How each study uses fasoracetam is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Aevi Genomic Medicine, LLC, a Cerecor company (6)
Studies
Open first, then newest update. How each study uses fasoracetam is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity DisorderCompletedPhase 1Aevi Genomic Medicine, LLC, a Cerecor companyNCT02286817Written as NFC-1
- Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsCompletedPhase 1Aevi Genomic Medicine, LLC, a Cerecor companyNCT02895906Written as NFC-1
- Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHDCompletedPhase 2/3Aevi Genomic Medicine, LLC, a Cerecor companyNCT02777931Written as NFC-1
- PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR MutationsCompletedPhase 2Aevi Genomic Medicine, LLC, a Cerecor companyNCT03609619Written as AEVI-001
- PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR MutationsCompletedPhase 2Aevi Genomic Medicine, LLC, a Cerecor companyNCT03265119Written as AEVI-001
- Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHDCompletedPhase 1Aevi Genomic Medicine, LLC, a Cerecor companyNCT03006367Written as NFC-1 100 mg
Codes
What other systems call fasoracetam · ClinicalTrials.gg INT014779
- UNII (FDA) 42O8UF5CJBFASORACETAMConfirmed FDA, Wikidata
- Wikidata Q5436839fasoracetamConfirmed FDA, Wikidata
- NCI Thesaurus C65623FasoracetamOne source FDA
- DrugBank DB16163One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 42O8UF5CJB | FASORACETAM | Confirmed FDA, Wikidata |
| Wikidata | Q5436839 | fasoracetam | Confirmed FDA, Wikidata |
| NCI Thesaurus | C65623 | Fasoracetam | One source FDA |
| DrugBank | DB16163 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.